DELAVIRDINE MESYLATE

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N6O3S.CH4O3S
Molecular Weight	552.667
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(NS(C)(=O)=O)=C4

InChI

InChIKey=MEPNHSOMXMALDZ-UHFFFAOYSA-N

InChI=1S/C22H28N6O3S.CH4O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20;1-5(2,3)4/h4-8,13-15,24-26H,9-12H2,1-3H3;1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H28N6O3S
Molecular Weight	456.561
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf | https://www.drugs.com/ppa/delavirdine.html

Delavirdine is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent DNA polymerase activities. Delavirdine does not compete with template:primer or deoxynucleoside triphosphates. HIV-2 RT and human cellular DNA polymerases alfa, gamma, or delta are not inhibited by delavirdine. In addition, HIV-1 group O, a group of highly divergent strains that are uncommon in North America, may not be inhibited by delavirdine. Delavirdine is marketed under the trade name Rescriptor, indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. .

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 reverse transcriptase 47 Target ID: CHEMBL247 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/26162497 \| https://www.ncbi.nlm.nih.gov/pubmed/10514285	Inhibitor 8146		21.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 145 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	Primary		Approved 8307	RESCRIPTOR Approved Use RESCRIPTOR Tablets are indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. The following should be considered before initiating therapy with RESCRIPTOR in treatment-naive patients. There are insufficient data directly comparing antiretroviral regimens containing RESCRIPTOR with currently preferred 3-drug regimens for initial treatment of HIV. In studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTIs) (currently considered suboptimal) to RESCRIPTOR plus 2 NRTIs, the proportion of patients receiving the regimen containing RESCRIPTOR who achieved and sustained an HIV-1 RNA level <400 copies/mL over 1 year of therapy was relatively low (see DESCRIPTION OF CLINICAL STUDIES). Resistant virus emerges rapidly when RESCRIPTOR is administered as monotherapy. Therefore, RESCRIPTOR should always be administered in combination with other antiretroviral agents. Launch Date 8.6011203E11

C_max

Value	Dose	Analyte	Population
2.18 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.88 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.23 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
35 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
18.8 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
26.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
180 μM × h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
4.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
6.18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	Disc. AE: Rash, Oral lesion... Other AEs: Fever, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Rash (grade 3-4, 36%) Oral lesion (1 patient) Function liver abnormal (2 patients) Headache (grade 4, 1 patient) Other AEs: Fever (grade 3, 1 patient) Thrombocytopenia (1 patient) Nausea (1 patient) Fatigue (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	unhealthy n = 412 Health Status: unhealthy Population Size: 412 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (3.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf

AEs

AE	Significance	Dose	Population
Fatigue	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Nausea	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Thrombocytopenia	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Oral lesion	1 patient Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Function liver abnormal	2 patients Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Fever	grade 3, 1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Rash	grade 3-4, 36% Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Headache	grade 4, 1 patient Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years n = 30 Health Status: unhealthy Condition: HIV infection Age Group: >18 years Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Rash	3.2% Disc. AE	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	unhealthy n = 412 Health Status: unhealthy Population Size: 412 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1695	substrate 1168 inhibitor 1789

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 208 CYP2C19 1410 P-gp 1401 MRP1 106 MRP2 363 MRP3 156 CYP1A2 1463	CYP3A 188 P-gp 1491	P-gp 252

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11225565/	negligible
MRP1 170	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
MRP2 452	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
MRP3 206	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3.0	yes [Ki 12.8 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3.0	yes [Ki 2.6 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3.0	yes [Ki 24 uM]
CYP3A 291	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/15544435/ Page: 3.0	yes [Ki 9.5 uM]	yes (co-administration study) Comment: coadministration of amprenavir with delavirdine resulted in an approximately 4-fold increase in amprenavir AUC to infinity (AUC∞) and a 6-fold increase in amprenavir Cmin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/15544435/ Page: 3.0
P-gp 1588	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/12180537/	yes
P-gp 1588	inhibitor 3185 Sources: https://aac.asm.org/content/48/4/1073	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3.0	likely
P-gp 1491	substrate 3264 Sources: https://aac.asm.org/content/48/4/1073	no
CYP3A 188	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3.0	yes	yes (co-administration study) Comment: Coadministration of RESCRIPTOR and drugs that induce CYP3A, such as rifampin, may decrease delavirdine plasma concentrations and reduce its therapeutic effect. With rifampin: 97% decrease in AUC Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:119573	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:119573
ChemicalBook	CB8292151	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8292151
MolPort	MolPort-003-846-188	https://www.molport.com/shop/molecule-link/MolPort-003-846-188
ZINC	ZINC000018516586	http://zinc15.docking.org/substances/ZINC000018516586
eMolecules	1989427	https://www.emolecules.com/cgi-bin/more?vid=1989427

PubMed

Title	Date	PubMed
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.	2001	11735608
[Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols].	2001 Dec	12113183
Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties.	2001 Nov	11724230
Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.	2001 Nov 15	11679930
Drugs for HIV infection.	2001 Nov 26	11723420
Can delavirdine substitute for ritonavir?	2001 Nov-Dec	11794866
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.	2001 Nov-Dec	11742431
HIV-protease inhibitors alter retinoic acid synthesis.	2001 Oct 19	11600826
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.	2002	12405866
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.	2002 Apr 1	11917237
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.	2002 Apr 15	11959068
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.	2002 Dec	12553483
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.	2002 Dec	12496743
Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase.	2002 Dec	12444075
Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.	2002 Dec 19	12477355
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.	2002 Jul	12180537
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.	2002 Jul	12069959
New developments in anti-HIV chemotherapy.	2002 Jul 18	12084468
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.	2002 Jul 5	12052725
Nelfinavir urinary stones.	2002 Mar	11832739
Rifampin and rifabutin drug interactions: an update.	2002 May 13	11996607
Delavirdine in rescue regimens.	2002 May-Jun	12064317
New anti-HIV agents and targets.	2002 Nov	12369088
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.	2002 Nov	12367719
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.	2002 Oct 18	12370521
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.	2002 Sep 1	12195349
Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy.	2002 Sep 6	12218397
Pharmacia pilots patent share for HIV drug.	2003 Apr	12680360
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	2003 Dec 15	14643315
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.	2003 Dec 5	14685057
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity.	2003 Feb	12616670
Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.	2003 Feb 5	12505781
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.	2003 Jan	12534646
Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.	2003 Jan	12502865
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.	2003 Jan 3	12478089
Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing.	2003 Jul 4	12824784
Comparison of nine resistance interpretation systems for HIV-1 genotyping.	2003 Jun	12924541
Protease inhibitor-sparing regimens: new evidence strengthens position.	2003 Jun 1	12946062
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.	2003 Jun 13	12799573
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.	2003 May	12800070
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.	2003 Nov 17	14612892
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.	2003 Oct	14640386
Identification and prediction of promiscuous aggregating inhibitors among known drugs.	2003 Oct 9	14521410
Pfizer announces free drug program.	2003 Sep	14596253
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C.	2003 Sep	14585205
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.	2004 Apr 1	15031785
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.	2004 Feb	15040537
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.	2004 Feb 26	14971897
Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials.	2004 Jan 31	14742351
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.	2004 May 6	15115397

Patents

Sample Use Guides

In Vivo Use Guide

HIV-1 infection (part of combination): Oral: 400 mg 3 times/day

Route of Administration: Oral

In Vitro Use Guide

In vitro anti-HIV-1 activity of delavirdine was assessed by infecting cell lines of lymphoblastic and monocytic origin and peripheral blood lymphocytes with laboratory and clinical isolates of HIV-1. IC50 and IC90 values (50% and 90% inhibitory concentrations) for laboratory isolates (n = 5) ranged from 0.005 to 0.030 uM and 0.04 to 0.10 uM, respectively. Mean IC50 of clinical isolates (n = 74) was 0.038 uM (range: 0.001 to 40 0.69 uM); 73 of 74 clinical isolates had an IC50

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:20:11 UTC 2022` Edited by `admin` on `Fri Dec 16 17:20:11 UTC 2022`
Record UNII	421105KRQE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DELAVIRDINE MESYLATE

Official Name

English

DELAVIRDINE MESILATE [JAN]

Common Name

English

DELAVIRDINE METHANESULFONATE [MI]

Common Name

English

DELAVIRDINE MESILATE

Common Name

English

DELAVIRDINE MESYLATE [ORANGE BOOK]

Common Name

English

DELAVIRDINE METHANESULFONATE

Common Name

English

U-90152S

Code

English

DELAVIRDINE MESYLATE [VANDF]

Common Name

English

RESCRIPTOR

Brand Name

English

Delavirdine mesylate [WHO-DD]

Common Name

English

PIPERAZINE, 1-(3-((1-METHYLETHYL)AMINO)-2-PYRIDINYL)-4-((5-((METHYLSULPHONYL)AMINO)-1H-INDOL-2-YL)CARBONYL)-, MONOMETHANESULPHONATE

Systematic Name

English

DELAVIRDINE MESYLATE [USAN]

Common Name

English

PIPERAZINE, 1-(3-((1-METHYLETHYL)AMINO)-2-PYRIDINYL)-4-((5-((METHYLSULFONYL)AMINO)-1H-INDOL-2-YL)CARBONYL)-, MONOMETHANESULFONATE

Systematic Name

English

DELAVIRDINE MESYLATE [HSDB]

Common Name

English

DELAVIRDINE MESILATE [MART.]

Common Name

English

1-(3-(ISOPROPYLAMINO)-2-PYRIDYL)-4-((5-METHANESULPHONAMIDOINDOL-2-YL)CARBONYL)PIPERAZINE MONOMETHANESULPHONATE

Systematic Name

English

1-[3-(Isopropylamino)-2-pyridyl]-4-[(5-methanesulfonamidoindol-2-yl)carbonyl]piperazine monomethanesulfonate

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97453